Nanoparticle compound for targeting lung small airway diseases as well as preparation method and application of nanoparticle compound

By constructing a nanodelivery system for mannotriose, hyaluronic acid and liposomes, the poor compliance and adverse reactions of existing COPD treatment methods are solved, and effective treatment for targeted pulmonary small airway diseases is achieved, which significantly reduces inflammation and improves Respiratory function.

CN118986935AInactive Publication Date: 2024-11-22AFFILIATED HOSPITAL OF JIANGXI UNIV OF TCM

Patent Information

Application Number
CN202411482119.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-23
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing treatment of chronic obstructive pulmonary disease (COPD) has poor compliance, many adverse reactions and poor results. There is a lack of effective nanomedicines targeting pulmonary small airway diseases, especially the use of mannex and hyaluronic acid has not yet been used. Being reported.

Method used

The nanodelivery system was constructed by self-assembly method, and nanoparticle complexes targeting lung small airway diseases were prepared, and the immune enhancement, anti-tumor and alleviating inflammatory response characteristics of mannex saccharide were used. , combined with the targeted delivery ability of liposomes, form nanoparticles with better stability and bioavailability, suitable for lung tissue damage repair and inflammation reduction.

Benefits of technology

Targeted lung enrichment is achieved, significantly alleviating inflammatory response and respiratory dysfunction, improving the stability and bioavailability of nanoparticles, simplifying the preparation and application process, and is suitable for the development and application of nanodrugs for lung small airway diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986935A_ABST
    Figure CN118986935A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and provides a nanoparticle compound targeting lung small airway diseases and a preparation method and application thereof, and the nanoparticle compound is manninotriose composite nanoparticles prepared from manninotriose, sodium hyaluronate and liposome. According to the invention, on the basis of the mass spectrometric data of the classical prescription buyuan decoction, the manninotriose, which is an active ingredient having an effect on the Beta-2 adrenergic receptor, is screened from the classical prescription buyuan decoction. The manninotriose forms a nano delivery system by using a nano-emulsion self-assembly method. The manninotriose-loaded nanoparticles have better stability and bioavailability, and can be enriched in the lung in a targeted manner, so that the effects of relieving inflammatory response and respiratory dysfunction and the like are more remarkable. Moreover, the preparation and application of the nanoparticle compound have simple operation steps, and are suitable for the development and application of nano drugs for targeting lung small airway diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a nanoparticle complex targeting small airway diseases of the lung, and a preparation method and application thereof. Background Art

[0002] Chronic obstructive pulmonary disease (COPD) has poor compliance, many adverse reactions and unsatisfactory effects when treated with conventional Western medicine alone. Pulmonary rehabilitation can improve dyspnea, health status and exercise tolerance in patients in the stable stage of COPD and improve the quality of life. Respiratory function training can enhance the strength of respiratory muscles and improve respiratory efficiency, thereby enhancing the respiratory function of the lungs. The breathing of the lungs is related to the function of the Zongqi moving through the respiratory tract to breathe and the function of the heart meridian to move qi and blood. The generation and deficiency of Zongqi are related to the rise and fall of the functions of the three organs of the lungs, spleen and kidneys. Traditional Chinese medicine believes that Zongqi deficiency is the original deficiency of COPD in the stable stage. Invigorating Zongqi is the fundamental method for treating COPD in the stable stage. Buyuan Decoction is a representative prescription for invigorating Zongqi. Buyuan Decoction (drug composition: 10g each of Atractylodes macrocephala, dried tangerine peel, angelica, Cimicifuga heracleifolia, Bupleurum chinense, Cynomorium songaricum, 15g each of Codonopsis pilosula and Cornus officinalis, 30g of Astragalus membranaceus, and 6g of roasted licorice).

[0003] The broad-target data of mass spectrometry of the classic prescription Buyuan Decoction contain 2554 compounds, of which non-target data contain 3623 compounds. SMILES were obtained from the PubChem database and literature by compound name and CAS number, and finally 4564 compounds with SMILES data were obtained. Among them, there are 1464 amino acids and their derivatives, 216 benzene and its derivatives, 65 alcohols and amines, 278 phenolic acids, 48 ​​glycerophospholipids, 7 glycerolipids, 136 nucleotides and their derivatives, 539 flavonoids, 32 quinones, 175 lignans and coumarins, 488 other types, 5 sphingolipids, 22 tannins, 4 tryptamines, choline, and pigments, 327 alkaloids, 200 terpenes, 284 organic acids, 96 heterocyclic compounds, 19 steroids, 31 fatty acyl compounds, and 128 lipids.

[0004] Mannotriose is a sugar compound, a white crystalline powder, derived from Rehmannia glutinosa. Mannotriose is the oligosaccharide component with the highest content in Rehmannia glutinosa. It can be prepared by hydrolyzing stachyose. Mannotriose has pharmacological activities such as promoting the proliferation of hematopoietic cells, improving immunity, lowering blood sugar, and anti-tumor.

[0005] Hyaluronic acid is an acidic mucopolysaccharide. D-glucuronic acid and N-acetylglucosamine are linked by β-1,3-glycosidic bonds, and disaccharide units are linked by β-1,4-glycosidic bonds. The disaccharide units can reach as many as 25,000. The molecular weight of hyaluronic acid in the body ranges from 1,000 to 20 million Daltons. With its unique molecular structure and physical and chemical properties, hyaluronic acid exhibits a variety of important physiological functions in the body. Studies have shown that hyaluronic acid is also very important for muscles. It can promote muscle stem cells to start muscle repair, such as lubricating joints, regulating the permeability of blood vessel walls, regulating protein, water and electrolyte diffusion and operation, and promoting wound healing.

[0006] However, there is no report on the combination of mannotriose and hyaluronic acid for the treatment of small airway diseases of the lung by establishing a liposome nano-drug delivery system. Summary of the invention

[0007] In order to solve the above technical problems, the present invention provides a nanoparticle complex targeting small airway diseases of the lung, and a preparation method and application thereof. The present invention constructs a nano delivery system with mannotriose, hyaluronic acid and liposomes by a self-assembly method. Mannotriose can improve immunity, fight tumors, reduce inflammatory responses, etc. The use of the nano delivery system makes the nanoparticles loaded with mannotriose have better stability and bioavailability, can be targeted and enriched in the lungs, and the effects of reducing inflammatory responses and respiratory dysfunction are more significant. Moreover, the preparation method of the mannotriose composite nanoparticles in the present invention and the operating steps during the application are relatively simple, and are also very suitable for the development, promotion and application of nano drugs for repairing lung tissue damage and reducing inflammation.

[0008] In order to achieve the above object, the present invention adopts the following technical solutions: A nanoparticle complex targeting small airway diseases of the lung, which is a mannotriose complex nanoparticle made of mannotriose, sodium hyaluronate and liposomes.

[0009] Preferably, the mannotriose is based on the mass spectrometry data of Buyuan Decoction, from which the active ingredient having an effect on Beta-2 adrenergic receptor is screened out.

[0010] Preferably, the liposome is any one or more of soybean lecithin (L-α-phosphatidylcholine, PC), oleyl phosphatidylcholine (DOPC), dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylethanolamine (DPPE), and distearoyl phosphatidylcholine (DSPC).

[0011] A method for preparing a nanoparticle complex targeting pulmonary small airway diseases comprises the following steps: Prepare a mixed solution I by mixing a hyaluronic acid-ethanol solution with a concentration of 1-20 mg / ml and a liposome-ethanol solution with a concentration of 10-200 mg / ml at a volume ratio of 1: (1-40); Adding a 1-10 mg / ml mannotriose-ethanol solution to the mixed solution I to prepare a mixed solution II, wherein the volume ratio of the mannotriose-ethanol solution to the mixed solution I is 1:(1-20); During the stirring process, the mixed solution II is added dropwise into the pure water system through a microfluidic chip to prepare a mixed solution III; The mixed solution III is continuously dialyzed in pure water; the solution after the dialysis is centrifuged to remove the precipitate; and then passed through a liposome propeller (100KDA), and the obtained supernatant is the mannotriose composite nanoparticles.

[0012] Preferably, after the mixed solution III is prepared, a process of magnetic stirring dispersion, continued stirring and ultrasonic treatment can be carried out; the magnetic stirring dispersion is carried out at room temperature; the continued stirring time is 0.2-0.5 hours; the ultrasonic treatment is 150-300W probe type ultrasound in a 36-38 degree Celsius water bath, and the ultrasonic treatment time is 5-25min.

[0013] Preferably, the pH value of the mannotriose composite nanoparticle solution is adjusted with hydrochloric acid until the pH value reaches 6.5-7.5, and then 1,2-hexanediol is added at a final concentration of 0.05-0.1 mg / ml.

[0014] The present invention also provides an application of a nanoparticle complex targeting small airway diseases of the lung, which is used as a target agonist targeting small airway diseases of the lung.

[0015] The present invention also provides an application of a nanoparticle complex targeting pulmonary small airway diseases as a dual-target agonist of Beta-2 adrenergic receptor and neutrophil elastase.

[0016] The application of nanoparticle complexes targeting small airway diseases in the preparation of therapeutic drugs for severe acute pancreatitis-related lung injury, including the repair of pancreatic and lung tissue damage and the reduction of inflammation.

[0017] Compared with the prior art, the present invention has the following technical effects: the present invention constructs a nano delivery system with mannotriose, sodium hyaluronate and liposomes by a self-assembly method. Mannotriose can improve immunity, fight tumors, reduce inflammatory reactions, etc. The nanoparticles loaded with mannotriose have better stability and bioavailability, can be targeted and enriched in the lungs, and the effects of reducing inflammatory reactions and relieving respiratory dysfunction are more significant. Moreover, the preparation method of the mannotriose composite nanoparticles in the present invention and the operating steps during application are relatively simple, and are also very suitable for the development and application of nano drugs targeting small airway diseases of the lungs. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 is the average particle size of the mannotriose composite nanoparticles prepared in Example 1 of the present invention; Figure 2 is the zeta potential of the mannotriose composite nanoparticles prepared in Example 1 of the present invention; Figure 3 This is a negative staining TEM transmission electron microscope scanning image of the mannotriose composite nanoparticles in Example 1 of the present invention; Figure 4 This is a diagram of the interaction between the target Beta-2 adrenergic receptor (7BZ2) and mannotriose in Example 1 of the present invention; Figure 5 This is a diagram of the interaction between the target neutrophil elastase (1h1b) and mannotriose in Example 1 of the present invention; Figure 6 This is the structure diagram of mannotriose; Figure 7 This is an in vivo imaging diagram of the enrichment of mannotriose composite nanoparticles in mouse lungs in Example 2 of the present invention. DETAILED DESCRIPTION

[0019] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Without departing from the spirit and essence of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention are within the scope of the present invention. The reagents, kits and instruments used in the following examples can all be obtained commercially, and the methods used in the examples are consistent with the conventional methods unless otherwise specified.

[0020] The present invention is based on the mass spectrometry data of the classic prescription Buyuan Decoction, from which active ingredients with good effects on Beta-2 adrenergic receptor are screened. The specific steps are as follows: Step 1: Establish a Beta-2 adrenergic receptor machine learning model and use the Beta-2 adrenergic receptor machine learning model to predict the activity of the compound.

[0021] Step 2: Molecular docking is used to screen compounds that have good effects on Beta-2 adrenergic receptors, and the free binding energy between the compounds and Beta-2 adrenergic receptors is calculated.

[0022] Step 3: Based on the results of steps 1 and 2, select compounds that are predicted to be active by the Beta-2 adrenergic receptor machine learning model and that are predicted to have good interactions by the molecular docking model.

[0023] Step 4: Use a molecular docking model to predict the interaction between the compound selected in step 3 and neutrophil elastase to determine whether the selected compound is a dual-target agonist.

[0024] Step 5: Molecular docking with Beta-2 adrenergic receptor as the receptor, molecular docking and free binding energy calculation with all 4560 compounds as ligands. Molecular docking and free binding energy calculation were performed in sequence with neutrophil elastase as the receptor.

[0025] Step 6: Based on the calculation results of free binding energy, it is predicted that the compound mannotriose can have a relatively good effect on both Beta-2 adrenergic receptor and neutrophil elastase at the same time, and is a dual-target agonist.

[0026] The calculation results are shown in Table 1 Table 1 Calculation results of free binding energy

[0027]

[0028] The present invention provides a method for preparing a nanoparticle complex targeting small airway diseases of the lung, comprising the following steps: A 1-20 mg / ml hyaluronic acid-ethanol solution and a 10-200 mg / ml liposome-ethanol solution are prepared in a volume ratio of 1:(1-40) to prepare a mixed solution I; wherein the preparation method of the mannotriose-ethanol solution, the hyaluronic acid-ethanol solution and the liposome-ethanol solution is as follows: 1-10 mg of mannotriose, 1-20 mg of hyaluronic acid and 10-200 mg of liposome are dissolved in 1-10 ml of anhydrous ethanol respectively, and the pH value is adjusted to 6.8-7.0, that is, a 1-10 mg / ml mannotriose-ethanol solution, a 1-20 mg / ml hyaluronic acid-ethanol solution and a 10-200 mg / ml liposome-ethanol solution are prepared. The pH value is adjusted using 0.5-3% hydrochloric acid. The liposome is any one or more of soybean lecithin (L-α-phosphatidylcholine, PC), oleyl phosphatidylcholine (DOPC), dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylethanolamine (DPPE), and distearoyl phosphatidylcholine (DSPC).

[0029] Adding a 1-10 mg / ml mannotriose-ethanol solution to the mixed solution I to prepare a mixed solution II, wherein the volume ratio of the mannotriose-ethanol solution to the mixed solution I is 1:(1-20); During the stirring process, the mixed solution II is added dropwise into the pure water system with a microfluidic chip to prepare a mixed solution III; after the mixed solution III is prepared, a process of magnetic stirring dispersion, continued stirring and ultrasonic treatment can be performed; the magnetic stirring dispersion is performed at room temperature; the continued stirring time is 0.2-0.5 hours; the ultrasonic treatment is 150-300W probe-type ultrasound in a 36-38 degree Celsius water bath, and the ultrasonic treatment time is 5-25 minutes.

[0030] The mixed solution III is continuously dialyzed in pure water using a dialysis bag with a molecular cutoff of 10-14 kDa, and the continuous dialysis time is 12-24 hours; the solution after dialysis is centrifuged to remove the precipitate; then it is passed through a liposome propeller (100 KDA), and the resulting supernatant is the mannotriose composite nanoparticle solution. The mannotriose composite nanoparticle solution is adjusted to a pH value of about 6.5-7.5 using diluted hydrochloric acid (0.5-2% wt), and then 1,2-hexanediol is added at a final concentration of 0.05-0.1 mg / ml to prevent the growth of microorganisms.

[0031] The technical solution of the present invention is further described in detail below in conjunction with embodiments. Example 1

[0032] (1) Take 1 mg of mannotriose, 1 mg of HA hyaluronic acid, and 20 mg of soybean lecithin, and dissolve them in 1 ml of ethanol (100%) respectively; adjust the pH value to about 7.0 with 0.5% hydrochloric acid to prepare a 1 mg / ml mannotriose-ethanol solution, a 1 mg / ml hyaluronic acid-ethanol solution, and a 20 mg / ml soybean lecithin-ethanol solution. Among them: mannotriose was purchased from Shanghai Taiwei Pharmaceutical Co., Ltd., CAS: 13382-86-0; hyaluronic acid was purchased from MERCK, item number 924474; soybean lecithin was purchased from Shanghai Taiwei Pharmaceutical Co., Ltd., CAS; 8002-43-5.

[0033] (2) A 1 mg / ml hyaluronic acid-ethanol solution and a 20 mg / ml soybean lecithin-ethanol solution were mixed to prepare a mixed solution I, the volume ratio of the two being 1:1, and the mixing method was magnetic rotation in a water bath for 15 min.

[0034] (3) Mixed solution I and 1 mg / ml mannotriose-ethanol solution were mixed in a volume ratio of 1:1 to prepare mixed solution II. The mixing method was also magnetically rotated in a water bath for 15 min.

[0035] (4) Take 100 ml of pure water system, use a microfluidic chip, and slowly flow mixed solution II drop by drop into the 100 ml pure water solution that is being stirred at a flow rate of 10 s / drop, then disperse it by magnetic stirring at room temperature, and then continue stirring for 0.2 hours. Finally, set 300W probe type ultrasound for 15 minutes in a 37 degree Celsius water bath to prepare mixed solution III.

[0036] (5) Transfer the mixed solution III to a pre-treated dialysis bag (MWCO: 10-14 kDa) and dialyze continuously in pure water for 12 hours, changing the solution several times during the period. After the dialysis is completed, transfer the solution in the dialysis bag to a centrifuge tube, centrifuge at 2700 rpm for 12 minutes to remove the precipitate, pass through a liposome propeller (100 KDA), and the resulting supernatant is the mannotriose composite nanoparticle solution. The mannotriose composite nanoparticle solution is adjusted to pH value using dilute hydrochloric acid (0.5% wt) until the pH value reaches about 7, and then add 1,2-hexanediol at a final concentration of 0.1 mg / ml to prevent the growth of microorganisms.

[0037] The particle size and potential of the prepared mannotriose composite nanoparticles were observed using a Brookhaven laser particle size analyzer 90Plus. The results are shown in Figure 1-2 shown. Figure 3 This is a negative staining TEM scanning image of mannotriose composite nanoparticles. Figure 4 This is the interaction diagram between the target Beta-2 adrenergic receptor (7BZ2) and mannotriose; Figure 5 This is a diagram of the interaction between the target neutrophil elastase (1h1b) and mannotriose in Example 1 of the present invention; Figure 6 The results show that the average particle size of the mannotriose composite nanoparticles is 128 nm, and the zeta potential is -23.91 mv, indicating that the mannotriose composite nanoparticles prepared by the present invention have a smaller average particle size and better stability. Example 2

[0038] (1) Take 10 mg of mannotriose, 10 mg of HA hyaluronic acid, and 200 mg of dipalmitoylphosphatidylcholine, and dissolve them in 1 ml of ethanol (100%) respectively; adjust the pH value to about 7.0 with 0.5% hydrochloric acid to prepare a 10 mg / ml mannotriose-ethanol solution, a 10 mg / ml hyaluronic acid-ethanol solution, and a 200 mg / ml dipalmitoylphosphatidylcholine-ethanol solution. Among them: mannotriose was purchased from Shanghai Taiwei Pharmaceutical Co., Ltd., CAS: 13382-86-0; hyaluronic acid was purchased from MERCK Company, item number 924474; dipalmitoylphosphatidylcholine was purchased from MERCK Company, CAS; 63-89-8.

[0039] (2) A 10 mg / ml hyaluronic acid-ethanol solution was first mixed with a 200 mg / ml dipalmitoylphosphatidylcholine-ethanol solution to prepare a mixed solution I, the volume ratio of the two being 1:40, and the mixing method was magnetic rotation in a water bath for 15 min.

[0040] (3) Mixed solution I and 10 mg / ml mannotriose-ethanol solution were mixed in a volume ratio of 20:1 to prepare mixed solution II. The mixing method was also magnetic rotation in a water bath for 15 min.

[0041] (4) Take 500 ml of pure water system, use a microfluidic chip, and slowly flow mixed solution II drop by drop into the stirring 500 ml pure water solution at a flow rate of 10 s / drop, then disperse it by magnetic stirring at room temperature, and then continue stirring for 0.2 hours. Finally, set 300W probe type ultrasound for 15 minutes in a 37 degree Celsius water bath to prepare mixed solution III.

[0042] (5) Transfer the mixed solution III to a pre-treated dialysis bag (MWCO: 10-14 kDa) and dialyze continuously in pure water for 12 hours, changing the solution several times during the process. After the dialysis is completed, transfer the solution in the dialysis bag to a centrifuge tube, centrifuge at 2700 rpm for 12 minutes to remove the precipitate, pass through a liposome propeller (100 KDA), and the resulting supernatant is the mannotriose composite nanoparticle solution. The mannotriose composite nanoparticle solution is adjusted to pH value using dilute hydrochloric acid (0.5% wt) until the pH value reaches about 7, and then add 1,2-hexanediol at a final concentration of 0.1 mg / ml to prevent the growth of microorganisms. Example 3

[0043] (1) Take 1 mg of mannotriose, 1 mg of hyaluronic acid, and 20 mg of dipalmitoylphosphatidylcholine, and dissolve them in 1 ml of ethanol (100%) respectively; adjust the pH value to about 7.0 with 0.5% hydrochloric acid to prepare a 1 mg / ml mannotriose-ethanol solution, a 1 mg / ml hyaluronic acid-ethanol solution, and a 20 mg / ml soybean lecithin-ethanol solution. Among them: mannotriose was purchased from Shanghai Taiwei Pharmaceutical Co., Ltd., CAS: 13382-86-0; hyaluronic acid was purchased from MERCK, item number 924474; dipalmitoylphosphatidylcholine was purchased from MERCK, CAS; 63-89-8.

[0044] (2) A 1 mg / ml hyaluronic acid-ethanol solution and a 20 mg / ml dipalmitoylphosphatidylcholine-ethanol solution were mixed to prepare a mixed solution I, the volume ratio of the two being 0.5:3, and the mixing method was magnetic rotation in a water bath for 15 min.

[0045] (3) Mixed solution I and 1 mg / ml mannotriose-ethanol solution were mixed in a volume ratio of 5:1 to prepare mixed solution II. The mixing method was also magnetic rotation in a water bath for 15 min.

[0046] (4) Take 100 ml of pure water system, use a microfluidic chip, and slowly flow mixed solution II drop by drop into the stirring 100 ml pure water solution at a flow rate of 10 s / drop, then disperse it by magnetic stirring at room temperature, and then continue stirring for 0.2 hours. Finally, set 300W probe type ultrasound for 15 minutes in a 37°C water bath to prepare mixed solution III.

[0047] (5) Transfer the mixed solution III to a pre-treated dialysis bag (MWCO: 10-14 kDa), and dialyze continuously in pure water for 12 hours, changing the solution several times during the period. After the dialysis is completed, transfer the solution in the dialysis bag to a centrifuge tube, centrifuge at 2700 rpm for 12 minutes to remove the precipitate, pass through a liposome propeller (100 KDA), and the resulting supernatant is the mannotriose composite nanoparticle solution. The mannotriose composite nanoparticle solution is adjusted to pH value using dilute hydrochloric acid (0.5% wt) until the pH value reaches about 7, and then add 1,2-hexanediol at a final concentration of 0.1 mg / ml to prevent the growth of microorganisms.

[0048] The mannotriose composite nanoparticles prepared in Example 1 were used to verify the effect of enrichment in rat lungs.

[0049] (1) Select healthy SPF-grade C57BL / 6 mice (male, 6 weeks old, weight range 20±2g) and divide 3 experimental mice into 3 groups, with 1 mouse in each group.

[0050] Group 1 and blank control group (treated with an equal volume of blank solvent, a single nebulized intratracheal administration of 20ul, and observation for 2 days after administration) (N=1) were subjected to in vivo imaging and photography at two points at 24 hours and 48 hours.

[0051] Group 2: FITC+mannotriose composite nanoparticle group, single nebulized tracheal administration of 20ul, observation for 2 days after administration) (N=1) Live imaging and photography were performed at 2 points for 24 hours and 48 hours.

[0052] Group 3: FITC fluorescent label group, single nebulized intratracheal administration of 20ul, observation for 2 days after administration) (N=1) Live imaging and photography were performed at 2 points for 24 hours and 48 hours.

[0053] (2) Fluorescent label molecule FITC, weigh 5 mg FITC and dissolve it in 0.1 mL DMSO, and take 20ul FITC solution for later use. Anesthesia: Sevoflurane breathing anesthesia machine (manufacturer: Yuyan Technology; model: ABM) In vivo imaging: Instrument: In vivo imaging instrument (manufacturer: Tanon; model: ABLX5 PRO); Parameters: Select "NIR700 channel, quantitative wavelength 497nm absorption value.

[0054] Depend on Figure 7 In summary, the single fluorescent label group diffused in various tissues and organs, and the FITC-labeled mannotriose composite nanoparticles had a better enrichment effect in the lungs and better metabolic efficiency after 48 hours.

[0055] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A nanoparticle complex targeting small airway diseases of the lung, characterized in that: The nanoparticle complex is mannotriose complex nanoparticles made of mannotriose, sodium hyaluronate and liposomes.

2. The nanoparticle complex targeting pulmonary small airway diseases according to claim 1, characterized in that: The mannotriose is based on the mass spectrometry data of Buyuan Decoction, from which the active ingredient having an effect on Beta-2 adrenergic receptor is screened out.

3. The nanoparticle complex targeting small airway diseases of the lung according to claim 1, characterized in that: The liposome is any one or more of soybean lecithin, oleyl lecithin, dipalmitoyl phosphatidylcholine, dipalmitoyl phosphatidylethanolamine, and distearoyl phosphatidylcholine.

4. The nanoparticle complex targeting small airway diseases of the lung according to claim 2, characterized in that: Based on the mass spectrometry data of Buyuan Decoction, active ingredients that have effects on Beta-2 adrenergic receptors were screened out. The specific steps are as follows: Step 1: Establish a Beta-2 adrenergic receptor machine learning model, and use the Beta-2 adrenergic receptor machine learning model to predict the activity of the compound; Step 2, using molecular docking to screen compounds that have a good effect on Beta-2 adrenergic receptors, and calculating the free binding energy between the compounds and Beta-2 adrenergic receptors; Step 3, based on the results of Step 1 and Step 2, select the compounds predicted to be active by the Beta-2 adrenergic receptor machine learning model and predicted to have good interactions by the molecular docking model; Step 4: using a molecular docking model to predict the interaction between the compound selected in step 3 and neutrophil elastase, and determining whether the selected compound is a dual-target agonist; Step 5, molecular docking with Beta-2 adrenergic receptor as receptor, molecular docking with all compounds as ligands and calculation of free binding energy; molecular docking with neutrophil elastase as receptor and calculation of free binding energy in turn; Step 6: Based on the calculation results of free binding energy, it is predicted that the compound mannotriose can act on both Beta-2 adrenergic receptor and neutrophil elastase at the same time, and is a dual-target agonist.

5. A method for preparing a nanoparticle complex targeting small airway diseases of the lung according to any one of claims 1 to 4, characterized in that: The following steps are involved: Prepare a mixed solution I by mixing a hyaluronic acid-ethanol solution with a concentration of 1-20 mg / ml and a liposome-ethanol solution with a concentration of 10-200 mg / ml at a volume ratio of 1: (1-40); Adding a 1-10 mg / ml mannotriose-ethanol solution to the mixed solution I to prepare a mixed solution II, wherein the volume ratio of the mannotriose-ethanol solution to the mixed solution I is 1:(1-20); During the stirring process, the mixed solution II is added dropwise into the pure water system through a microfluidic chip to prepare a mixed solution III; The mixed solution III is continuously dialyzed in pure water; the solution after the dialysis is centrifuged to remove the precipitate; and then passed through a liposome propeller, and the obtained supernatant is the mannotriose composite nanoparticles.

6. The method for preparing the nanoparticle complex targeting small airway diseases of the lung according to claim 5, characterized in that: After the mixed solution III is prepared, a process of magnetic stirring dispersion, continued stirring and ultrasonic treatment is performed; the magnetic stirring dispersion is performed at room temperature; the continued stirring time is 0.2-0.5 hours; the ultrasonic treatment is 150-300W probe type ultrasound in a water bath at 36-38 degrees Celsius, and the ultrasonic treatment time is 5-25 minutes.

7. The method for preparing the nanoparticle complex targeting small airway diseases of the lung according to claim 5, characterized in that: The pH value of the mannotriose composite nanoparticle solution was adjusted with hydrochloric acid until the pH value reached 6.5-7.5, and then 1,2-hexanediol was added at a final concentration of 0.05-0.1 mg / ml.

8. A use of the nanoparticle complex targeting pulmonary small airway diseases according to any one of claims 1 to 4, characterized in that: Used as a target agonist for lung small airway diseases.

9. The use of the nanoparticle complex targeting small airway diseases of the lung according to claim 8, characterized in that: As a dual-target agonist of Beta-2 adrenergic receptor and neutrophil elastase.

10. Use of the nanoparticle complex targeting pulmonary small airway diseases according to any one of claims 1 to 4 in the preparation of a therapeutic drug for severe acute pancreatitis-related lung injury.

Citation Information

Patent Citations

  • Nano-drug carrier, nano-drug preparation, preparation method and application

    CN112220929A

  • Nanoparticle compound for inhibiting lung injury related to severe acute pancreatitis as well as preparation method and application of nanoparticle compound

    CN117224488A

  • Pharmaceutical compositions and uses thereof

    IN201917020767A

  • Sugar-modified liposome and products comprising the liposome

    US20060193906A1

Cited By

  • Nanoparticle compound for targeting lung small airway disease as well as preparation method and application of nanoparticle compound

    CN120168409A

  • A nanoparticle complex targeting small airway disease of the lung and its preparation method and application

    CN120168409B